BMY withdraws Opdivo MAA in second-line HCC: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/09/news_detail_002809.jsp&mid=WC0b01ac058004d5c1 http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500234787 I do not know the reason for the negative CHMP viewpoint that triggered the withdrawal.